<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03560609</url>
  </required_header>
  <id_info>
    <org_study_id>17-01360</org_study_id>
    <nct_id>NCT03560609</nct_id>
  </id_info>
  <brief_title>Optic Nerve Head Structural Response to IOP Elevation in Patients With Keratoconus</brief_title>
  <official_title>Optic Nerve Head Structural Response to IOP Elevation in Patients With Keratoconus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The mechanism by which vision loss in glaucoma occurs is still unknown, but it is clear that
      increased Intraocular Pressure (IOP) is a major risk factor. It is also thought that the
      lamina cribrosa (LC) is a site of primary damage during the pathogenesis of the disease. The
      changes caused by intraocular pressure (IOP) modulation at the level of the optic nerve head
      and LC will be evaluated in the present study. Subjects with keratoconus exhibit abnormal
      collagen properties that can impair their LC behavior. By evaluating their lamina
      biomechanical response we can advance our understanding on the role of the lamina in glaucoma
      pathogenesis. A better understanding of the process will ultimately lead to improved
      detection and management of glaucoma.

      It is hypothesized that subjects with keratoconus have an abnormal biomechanical response of
      the lamina cribrosa in response to IOP modulation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2018</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LC measurements measured in microns</measure>
    <time_frame>1 Day</time_frame>
    <description>These micron measurements will be obtained from in vivio OCT images</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anterior laminar displacement measured in microns</measure>
    <time_frame>1 Day</time_frame>
    <description>These micron measurements will be obtained from in vivio OCT images</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Keratoconus</condition>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Subjects With Keratoconus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects with Glaucoma</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ophthalmodynamometer</intervention_name>
    <description>The ODM (Baillart ophthlmodynamometer) is a disc attached to a piston that induces a controlled force on a fixed area. The device will be used to apply a pressure within the range of 10 mmHg - 50 mmHg 4 times to each eye. Each increase of pressure will last approximately 30 seconds. The device is FDA approved and will be used as routinely used in clinical practice</description>
    <arm_group_label>Subjects With Keratoconus</arm_group_label>
    <arm_group_label>Subjects with Glaucoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Goldmann applanation tonometer</intervention_name>
    <description>The Goldmann applanation tonometer (Haag-Streit, Basel, Switzerland) measures the IOP after the eye is numbed with a drop of anesthetic (proparacaine), which is approved by the FDA. Proparacaine is part of routine patient care using a tonometer regardless of participation in this study. The instrument's tip lightly touches the surface of the cornea and the IOP is measured. The device is FDA approved is routinely used in clinical practice.</description>
    <arm_group_label>Subjects With Keratoconus</arm_group_label>
    <arm_group_label>Subjects with Glaucoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pentacam</intervention_name>
    <description>This device maps the cornea and provides pachymetry, topography and corneal aberration maps. The device is FDA approved and routinely used in clinical practice.</description>
    <arm_group_label>Subjects With Keratoconus</arm_group_label>
    <arm_group_label>Subjects with Glaucoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ORA</intervention_name>
    <description>ORA is an air puff tonometer that applies controlled force to flattens the cornea and provides the corneal hysteresis and corneal resistance factor. The device is FDA approved and routinely used in clinical practice.</description>
    <arm_group_label>Subjects With Keratoconus</arm_group_label>
    <arm_group_label>Subjects with Glaucoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optical Coherence Tomography (OCT)</intervention_name>
    <description>OCT is a non-contact,real-time, high resolution, and reproducible imaging modality that provides in-vivo optical cross-sectional scanning of the retina, the ONH and of the anterior segment structures including the cornea. Clinical staff will perform subject testing, not research coordinators. Information about these non-FDA approved OCTs and the multi-modal adaptive optics system can be found in appendices A, B, C, and D. With all devices, the participant sits in a slit lamp like frame. A low power laser light is projected toward the back of their eyes while the subject fixates on a target. None of the systems produce harmful radioactive radiation.</description>
    <arm_group_label>Subjects With Keratoconus</arm_group_label>
    <arm_group_label>Subjects with Glaucoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Candidates must meet the following inclusion criteria in order to participate in the study.

          -  Ability to provide informed consent and to understand the study procedures

        Keratoconus:

          -  Clinical diagnosis of keratoconus

          -  Central thinning of the cornea

          -  Abnormal posterior ectasia.

        Glaucoma:

          -  Glaucomatous ONH abnormality: rim thinning, notching, undermining (excavation) or
             diffuse or localized RNFL defects that are characteristic of glaucoma.

          -  Two consecutive abnormal SITA standard perimetry tests with GHT outside normal limits.

        Exclusion Criteria:

        Candidates that meet any of the exclusion criteria at baseline will be excluded from study
        participation.

          -  Media opacity (e.g. lens, vitreous, cornea).

          -  Strabismus, nystagmus or a condition that would prevent fixation.

          -  Diabetes with evidence of retinopathy.

          -  Previous intraocular surgery or ocular trauma (with the exception of laser procedures
             and subjects that have undergone uneventful cataract surgery more than 6 months from
             enrollment date).

          -  Neurological and non-glaucomatous causes for visual field damage.

          -  Any intraocular non-glaucomatous ocular disorders.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chaim Wollstein</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zena Moore</last_name>
    <phone>+1 929 455 5539</phone>
    <email>Zena.Moore@nyulangone.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward Pei</last_name>
      <phone>646-501-8741</phone>
      <email>edward.pei@nyumc.org</email>
    </contact>
    <investigator>
      <last_name>Chaim Wollstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 6, 2018</study_first_submitted>
  <study_first_submitted_qc>June 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2018</study_first_posted>
  <last_update_submitted>May 22, 2020</last_update_submitted>
  <last_update_submitted_qc>May 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Deidentified data will be shared upon request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Data is available upon reasonable request indefinitely</ipd_time_frame>
    <ipd_access_criteria>Requests should be directed to Gadi.wollstein@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

